We work on drug discovery by combining our proprietary global top level antibody engineering and cyclic peptide technology and biological hypothesis of disease causing mechanism to solve the unmet medical needs.

Recycling Antibody®

The our proprietary Recycling Antibody® technology, in contrast to conventional antibodies which can only bind to the antigen once, enables a single antibody molecule to bind to an antigen multiple times. This is achieved by engineering the antibody to dissociate from the antigen at acidic pH within the endosome. Recycling Antibody® technology has been applied to create FDA-approved product, ENSPRYNG® (satralizumab), and we have multiple recycling antibodies that are now being tested in clinical study and in the drug discovery stage.

Recycling Antibody® is a registered trademark of Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan)

Reference Article:

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization

Nature Biotechnology volume 28, pages 1203–1207 (2010)

Source Link: Nature Biotechnology

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases

Scientific Reports volume 7, Article number: 1080 (2017)

Source Link: Nature Biotechnology
< Back